A liquid crystal composition includes one or more compounds represented by Chemical Formula 1: ##STR00001## wherein in Chemical Formula 1, A1, A2, L.sub.1 to L.sub.8, R, R, Z.sub.1 to Z.sub.3, n1, and n2 are the same as described in the specification.

A liquid crystal composition includes one or more compounds represented by Chemical Formula 1: ##STR00001## wherein in Chemical Formula 1, A1, A2, L.sub.1 to L.sub.8, R, R, Z.sub.1 to Z.sub.3, n1, and n2 are the same as described in the specification.

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

A liquid crystal composition includes one or more compounds represented by Chemical Formula 1:

##STR00001## wherein in Chemical Formula 1, A1, A2, L.sub.1 to L.sub.8, R, R, Z.sub.1 to Z.sub.3, n1, and n2 are the same as described in the specification.

A liquid crystal composition includes one or more compounds represented by Chemical Formula 1:

##STR00001## wherein in Chemical Formula 1, A1, A2, L.sub.1 to L.sub.8, R, R, Z.sub.1 to Z.sub.3, n1, and n2 are the same as described in the specification.